About GeneCentric Therapeutics
GeneCentric Therapeutics is a private company based in Durham, North Carolina. It has reported $21,555,973 raised in seven offerings on Form D since September 2011.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 4, 2025 | Jun 20, 2025 | $1,999,967of $5.0M target | 9 | $222K | EquityRule 506(b) | Form D ↗ |
| Sep 8, 2022 | Sep 20, 2022 | $2,500,000of $3.5M target | 1 | $2.5M | DebtRule 506(b) | Form D ↗ |
| Sep 22, 2021 | Oct 7, 2021 | $4,500,000of $7.5M target | 1 | $4.5M | EquityRule 506(b) | Form D ↗ |
| Dec 29, 2020 | Jan 13, 2021 | $1,200,000fully sold | 4 | $300K | DebtRule 506(b) | Form D ↗ |
| Dec 22, 2016 | Jan 5, 2017 | $6,105,996of $8.6M target | 4 | $1.5M | EquityRule 506(b) | Form D ↗ |
| Jun 19, 2013 | Jul 2, 2013amended Jul 11, 2014 | $5,000,010fully sold | 4 | $1.2M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Sep 2, 2011 | Sep 16, 2011 | $250,000fully sold | 2 | $125K | Equity06 | Form D ↗ |
| Total, seven offerings | $21,555,973 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on GeneCentric Therapeutics's Form D filed Jun 20, 2025.
CT
Clay Thorp
Director
MM
Michael Milburn
Executive officer and director
AL
Arnold Levine
Director
CP
Charles Perou
Director
PR
Prasanth Reddy
Director
MG
Myla Lai-Goldman
Director
DH
Don Hardison
Director
Earlier filings also listed Ellen Lubman (director, last listed Sep 2022) and David Hayes (executive officer and director, last listed Jan 2017).